Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Thematic (Sector/Industry)

United states Health care / Thematic (Sector/Industry)

<ul><li>More than symbolic, although not transformational on its own. </li><li>The executive order (EO) signed on April 18 contains several concrete mechanisms: national priority review vouchers for Breakthrough Designated psychedelic therapies;</li><li>a ‘Right to Try’ (RTT) expansion creating a pre-approval patient access pathway; a sequenced rescheduling commitment directing the Attorney General to initiate reviews upon Phase 3 completion; $50 million in ARPA-H funding matched to state research programs; and IND clearance for Ibogaine.</li></ul>

More than symbolic, although not transformational on its own. The executive order (EO) signed on April 18 contains several concrete mechanisms: national priority review vouchers for Breakthrough Designated psychedelic therapies;a ‘Right to Try’ (RTT) expansion creating a pre-approval patient access pathway; a sequenced rescheduling commitment directing the Attorney General to initiate reviews upon Phase 3 completion; $50 million in ARPA-H funding matched to state research programs; and IND clearance for Ibogaine.

Thoughts on Executive Order on Psychedelics: Process Positive but Structural Gaps Remain